DocGo (NASDAQ:DCGO) Posts Earnings Results, Misses Estimates By $0.10 EPS

DocGo (NASDAQ:DCGO) released its quarterly earnings data on Monday. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.10), Zacks reports. DocGo had a negative return on equity of 38.52% and a negative net margin of 62.23%.The business had revenue of $75.55 million during the quarter, compared to analysts’ expectations of $72.48 million.

Here are the key takeaways from DocGo’s conference call:

• Raised 2026 revenue guidance to $300M–$315M while keeping full-year adjusted EBITDA guidance unchanged at a $5M–$10M loss, reflecting stronger top-line momentum but continued near-term profitability targets that remain negative.
• SteadyMD accelerated in Q1 with >$9M revenue, ~1.1M visits and lab orders (up 38% YoY), and a new online-pharmacy contract for weight‑loss and general clinical services—management said SteadyMD drove the majority of the guidance increase.
• Home-health and mobile phlebotomy are scaling quickly—management projects up to 75% growth in mobile phlebotomy in 2026, expanding into new territories (Upstate NY, Pennsylvania, launching Florida) and integrating lab systems and AI to improve margins.
• Margin pressures and higher operating costs weighed on results—Q1 adjusted EBITDA was a $(10.2)M loss, with management citing temporary labor inefficiencies from rapid SteadyMD hiring and higher fuel costs as near-term drags on gross margin.
• Near-term cash/working-capital pressure—cash fell to $59.9M at quarter-end, management collected ~$8M on April 1 but said roughly $13M from NYC HPD remains outstanding and is expected to be collected over the balance of 2026.

DocGo Stock Up 0.5%

DCGO opened at $0.59 on Wednesday. The firm’s fifty day simple moving average is $0.64 and its two-hundred day simple moving average is $0.82. DocGo has a 52-week low of $0.49 and a 52-week high of $1.78. The company has a market cap of $58.76 million, a price-to-earnings ratio of -0.31 and a beta of 1.02.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Stifel Nicolaus decreased their target price on shares of DocGo from $4.00 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 price target on shares of DocGo in a report on Tuesday, March 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of DocGo in a research report on Monday. Finally, Canaccord Genuity Group decreased their price objective on DocGo from $1.50 to $1.00 and set a “hold” rating for the company in a report on Wednesday, March 25th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, DocGo currently has a consensus rating of “Hold” and an average target price of $2.38.

Institutional Trading of DocGo

Several large investors have recently made changes to their positions in DCGO. Neuberger Berman Group LLC acquired a new stake in shares of DocGo in the fourth quarter valued at $29,000. Cerity Partners LLC acquired a new position in DocGo during the 2nd quarter worth about $37,000. Public Employees Retirement System of Ohio purchased a new position in DocGo during the 4th quarter valued at about $40,000. Engineers Gate Manager LP purchased a new position in DocGo during the 2nd quarter valued at about $52,000. Finally, Jain Global LLC acquired a new position in DocGo in the 4th quarter valued at about $70,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

DocGo News Roundup

Here are the key news stories impacting DocGo this week:

• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating on DocGo, which may have helped support sentiment by signaling continued confidence in the stock’s longer-term recovery. DocGo (NASDAQ:DCGO) Receives Overweight Rating from Cantor Fitzgerald
• Neutral Sentiment: Management’s Q1 2026 earnings call highlighted strong revenue growth, but also pointed to operational challenges, suggesting progress on sales without a clean margin story yet. DocGo Inc (DCGO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational Challenges
• Negative Sentiment: DocGo’s Q1 results showed a wider-than-expected loss of $0.15 per share versus the expected $0.02 loss, even though revenue came in above estimates at $75.55 million. That earnings miss is the main pressure point for the stock. DocGo Inc. (DCGO) Reports Q1 Loss, Beats Revenue Estimates

DocGo Company Profile

DocGo, Inc is a U.S.-based integrated healthcare company that delivers on-demand and mobile healthcare services. The company’s business model centers on deploying customized medical clinics paired with a digital care platform to bring primary and acute care directly to patients. Through a combination of telemedicine and over-the-road medical units, DocGo addresses routine medical exams, chronic disease management, occupational health screenings, specialist consultations and urgent care interventions.

In addition to its mobile clinic fleet, DocGo’s digital platform offers 24/7 virtual care, facilitating remote consultations via video, phone or secure messaging.